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Abstract
Background: Experiments in mice initially suggested a role for the protein angiopoietin-like 8 (ANGPTL8) in
glucose homeostasis. However, subsequent experiments in model systems have challenged this proposed role.
We sought to better understand the importance of ANGPTL8 in human glucose homeostasis by examining the
association of a null mutation in ANGPTL8 with fasting glucose levels and risk for type 2 diabetes.
Methods: A naturally-occurring null mutation in human ANGPTL8 (rs145464906; c.361C > T; p.Q121X) is carried
by ~1 in 1000 individuals of European ancestry and is associated with higher levels of plasma high-density
lipoprotein cholesterol, suggesting that this mutation has functional significance. We examined the association of
p.Q121X with fasting glucose levels and risk for type 2 diabetes in up to 95,558 individuals (14,824 type 2 diabetics
and 80,734 controls).
Results: We found no significant association of p.Q121X with either fasting glucose or type 2 diabetes (p-value = 0.90
and 0.65, respectively). Given our sample sizes, we had >98 % power to detect at least a 0.23 mmol/L effect on plasma
glucose and >95 % power to detect a 70 % increase in risk for type 2 diabetes.
Conclusion: Disruption of ANGPTL8 function in humans does not seem to have a large effect on measures of glucose
tolerance.
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Background
In type 1 and to a lesser extent in type 2 diabetes, the
insulin-producing beta cells of the pancreas undergo
destruction and exhibit decreased function. Recovered in-
sulin production by abrogating this process has important
therapeutic implications for individuals suffering from
diabetes mellitus. A study in mice demonstrated that pan-
creatic beta cell proliferation is stimulated by a 198-amino
acid protein named betatrophin (also known as Lipasin
and ANGPTL8), leading to improved glucose tolerance
[1]. Injection of betatrophin-expressing plasmids into
mice resulted in increased beta cell replication and ultim-
ately increased beta cell number and pancreatic beta cell
mass. However, subsequent murine experiments of beta-
trophin have largely been neutral with respect to glucose
alterations and overexpression of ANGPTL8 showed no
abnormalities in glucose homeostasis [2, 3]. In addition,
Angptl8-/- mice did not demonstrate impaired glucose
tolerance [2, 4]. Although its role in glucose homeostasis
is still being elucidated, ANGPTL8 is known to have a role
in the regulation of lipid metabolism, possibly through
activation of a related protein, angiopoietin-like 3 [5].
Several experiments have shown that Angptl8 null mice
have lower triglyceride levels and conversely, that
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overexpression of ANGPTL8 increases triglyceride levels
[2, 4, 5]. Taken together, findings in model systems suggest
that whereas a role for ANGPTL8 in beta cell proliferation
is uncertain, ANGPTL8 is consistently linked to triglycer-
ide concentrations.
Null mutations can be used to inform on the effect
of a gene in humans. We have previously reported a
naturally-occurring null mutation in human ANGPTL8
(rs145464906; c.361C > T; p.Q121X). ANGPTL8 p.Q121X
is estimated to be carried by 1 in 1000 individuals of
European ancestry and 1 in 10,000 African-Americans [6].
Plasma high-density lipoprotein cholesterol is 10 mg/dl
higher (p-value = 5 x 10-11) and triglyceride concentration
is 15 % lower (p-value = 0.003) in carriers of ANGPTL8
p.Q121X [6].
The lipid phenotype demonstrated by carriers of
ANGPTL8 p.Q121X suggests that this naturally occur-
ring mutation has functional significance and allows us
to test the hypothesis that carrying ANGPTL8 p.Q121X
also perturbs glucose homeostasis in humans. Previously,
we have shown that ANGPTL8 p.Q121X was not associ-
ated with fasting glucose in two studies (n < 15,000) [6].
Here, we aimed to determine the association of ANGPTL8
p.Q121X with two measures of glucose homeostasis –
fasting glucose level and type 2 diabetes status in up to




In silico analysis was performed to predict the effect of
ANGPTL8 p.Q121X (rs145464906) mutation on transcrip-
tion. We predicted whether the ANGPTL8 p.Q121X mu-
tation resulted in nonsense mediated decay using RNA
sequencing transcript isoform data publically available
from the Genotype-Tissue Expression (GTEx) project
(http://www.gtexportal.org/) and a predictive model im-
plemented in MAMBA (http://www.well.ox.ac.uk/~rivas/
mamba) [7, 8].
Study participants
Analysis was limited to subjects of self-reported European
ancestry. Studies contributing summary results included
the BioImage Study [9], the Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) Con-
sortium Diabetes Working Group [10], and studies from
the T2D-GENES consortium with > 5 minor alleles for
ANGPTL8 p.Q121X (KORA and UK) [11]. The BioImage
Study and the KORA and UK studies from the T2D-
GENES consortium have been approved by the MIT IRB
(#1010004095, #0912003615 #1107004579, respectively).
The CHARGE Diabetes Working Group consists of 27
European Ancestry studies and all participating studies
were approved by local institutional review committees.
All subjects have provided written informed consent.
Genotyping and quality control
All study participants were genotyped on the HumanEx-
ome BeadChip v.1.0 or v1.1 (Illumina) for ANGPTL8
p.Q121X and called using joint calling [12], GenomeStu-
dio or zCall [13]. Quality control involved checking con-
cordance to GWAS data and excluding those individuals
missing >5 % genotypes, population clustering outliers,
individuals with high inbreeding coefficients or hete-
rozygote rates, individuals with gender mismatches, one
individual from duplicate pairs, and individuals with an
unexpectedly high proportion of identity-by-descent
sharing, with consideration for family studies, based on
high-quality variants. All contributing studies used an addi-
tive coding of variants to the minor allele.
Phenotypes
Association analyses were performed for fasting glucose
and type 2 diabetes individually by cohort and summary
statistics were shared. In the BioImage Study, type 2 dia-
betes was defined as individuals taking a medication for
diabetes, having a fasting glucose > 126 mg/dl or having
been told that he/she had diabetes. Type 2 diabetes was
defined in the CHARGE Consortium Diabetes Working
Group according to Wessel et al [10], and in the T2D-
GENES Consortium according to Voight et al [14]. Indi-
viduals with a diagnosis of diabetes were excluded from
the fasting glucose and insulin analyses to avoid the vari-
able effects of diabetes medications on the quantitative
traits.
Statistical analyses
Two primary analyses were performed separately by study
in available participants: (1). linear regression of fasting
glucose levels with an additive coding of ANGPTL8
p.Q121X adjusting for age, sex, and principal components
of ancestry; and (2). logistic regression of type 2 diabetes
with an additive coding of ANGPTL8 p.Q121X adjusting
for age, sex, and principal components of ancestry. Counts
of the number of ANGPTL8 p.Q121X mutation carriers
were obtained in type 2 diabetes cases and controls.
Additionally, in 47,388 we analyzed the association of
ANGPTL8 p.Q121X with fasting insulin levels adjusted
for BMI, age, sex, and principal components of ancestry.
For the outcomes of fasting glucose and fasting insulin
levels, statistical evidence from each study was combined
using fixed-effects inverse variance meta-analysis. Hetero-
geneity of effects between studies was ruled out (p > 0.05).
For the outcome of type 2 diabetes, we performed
meta-analyses by using Cochran-Mantel-Haenszel statis-
tics for stratified 2x2 tables. The Cochran-Mantel-Hanszel
method combines score statistics rather than Wald
Clapham et al. BMC Endocrine Disorders  (2016) 16:7 Page 2 of 4
statistics. As an alternate approach, we performed a fixed-
effects inverse variance meta-analysis on the betas and
standard errors from the individual study results. Using a
fixed-effects inverse variance meta-analysis did not change
the results.
All analyses were performed using the software program
R version 2.15. We estimated statistical power to detect
association of ANGPTL8 p.Q121X with fasting glucose
and type 2 diabetes using the Genetic Power Calculator
(http://pngu.mgh.harvard.edu/~purcell/gpc/) [15].
Results
The lipid phenotype previously demonstrated by carriers
of ANGPTL8 p.Q121X suggests that this naturally oc-
curring mutation has functional significance. In addition,
using in silico predictions, we found that ANGPTL8
p.Q121X results in nonsense mediated decay of the
RNA transcript and partial knockdown of the resulting
protein (Additional file 1: Figure S1).
All participants were of self-reported European ances-
try. 69,854 individuals without type 2 diabetes were
available for the analysis of fasting glucose levels. In ana-
lysis for type 2 diabetes status, 14,824 individuals with a
diagnosis of type 2 diabetes were compared to 80,734
controls (Additional file 1: Table S1). 24 (0.16 %) of the
type 2 diabetes cases were heterozygous carriers of the
minor allele for ANGPTL8 p.Q121X whereas 142 (0.18 %)
of the controls were heterozygous carriers.
We combined evidence from all available studies and
performed a fixed-effects meta-analysis for the associ-
ation of p.Q121X with fasting glucose levels. We found
no evidence for association of p.Q121X with fasting
glucose levels (beta = 0.002 mmol/L; 95 % conference
interval[CI] = (-0.025, 0.029); p-value = 0.90) (Table 1).
For the outcome of type 2 diabetes, we used Cochran-
Mantel-Haenszel meta-analysis to combine the counts
across the studies given the low number of type 2 dia-
betes cases with the p.Q121X mutation. We found no
evidence for association of p.Q121X with type 2 diabetes
(Fig. 1, OR = 0.88, 95 % CI = 0.57 – 1.36, p-value = 0.65).
Additionally, we found no evidence of association for
fasting insulin levels adjusted for BMI with ANGPTL8
p.Q121X in 47,388 individuals with fasting insulin avail-
able within CHARGE (3 % change; p = 0.43).
We estimated statistical power to detect each of these
associations given our analyzed sample sizes. Power
calculations indicate that with a sample size of 69,854
we had >98 % power to detect a 0.23 mmol/L (1/2-stand-
ard deviation; 4.2 mg/dL) effect of p.Q121X on fasting
glucose at an alpha level of 0.05. Given 14,824 type 2 dia-
betes cases and 80,734 controls, we have >95 % power to
detect a genotype relative risk for carriers of > 1.7 and >
85 % power to detect a genotypic relative risk for carriers
of > 1.6 at an alpha level of 0.05.
Discussion
We find that carrying a null mutation in human
ANGPTL8 is neither associated with fasting glucose nor
risk for type 2 diabetes in analyses involving up to
95,558 individuals. These results are consistent with
findings from a preliminary analysis of individuals carry-
ing ANGPTL8 p.Q121X with fasting glucose in Peloso,
et al [6], in which no significant association between
ANGPTL8 p.Q121X and fasting glucose levels was iden-
tified in <15,000 individuals, which only had 45 % power
to detect a 0.23 mmol/L (1/2-standard deviation; 4.2 mg/
dL) effect of p.Q121X on fasting glucose at an alpha level
of 0.05. However, the larger sample size utilized in our
study allowed for 98 % power and a better estimation of
the impact of ANGPTL8 p.Q121X on fasting glucose
levels. This study also expands upon the phenotyping of
the carriers of this allele in that we were able to examine
association of ANGPTL8 p.Q121X with a diagnosis of type
2 diabetes and with fasting insulin levels, and to ask a tar-
geted hypothesis that may not reach an exome chip-wide
significance level (p < 3 × 10−7 for fasting glucose and
p < 4.5 × 10−7 for type 2 diabetes) as was explored in
Wessel, et al [10].
While our results do not support the role of
ANGPTL8 inhibitors for treatment of type 2 diabetes,
there remains evidence that ANGPTL8 inhibition re-
mains a viable anti-triglyceride target [2, 6]. The human
genetic analysis presented here provides evidence that
an ANGPTL8 inhibitor aimed at lowering plasma trigly-
ceride levels will not have a major effect on glucose
tolerance in humans.
Table 1 Association of ANGPTL8 p.Q121X with plasma glucose
Study N Effect size Standard error p
BioImage 4,072 0.080 0.19 0.70
CHARGE 49,838 -0.005 0.05 0.92
T2D-GENES 15,944 0.002 0.01 0.89
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Fig. 1 Association of ANGPTL8 p.Q121X with type 2 diabetes in
14,824 cases and 80,734 controls. In each study, we tested the
association of carrier status with type 2 diabetes. Meta-analysis was
performed using the Cochran-Mantel Haensel statistics for stratified
2-by-2 tables
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Some limitations deserve mention. The initial thera-
peutic hypothesis from model systems related to gain of
gene function; loss of gene function as assessed by
p.Q121X may not necessarily lead to phenotypic effects
in a direction opposite to gain of gene function. In
addition, due to the scarcity of the allele, we were able
to assess only heterozygous carriers of the allele. It is
possible that there is a recessive effect on fasting glucose
levels or type 2 diabetes status that would be unmasked
only in individuals homozygous for the ANGPTL8 muta-
tion. The scarcity of the null mutation also limits our
statistical power, and we are unable to rule out modest
effects on glucose and type 2 diabetes.
Conclusion
While ANGPTL8 has been shown to robustly associate
with plasma triglyceride levels, our results do not sup-
port a role for ANGPTL8 in glucose homeostasis in
humans.
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